Present Value of Free Cash Flow to the Firm (FCFF)
In discounted cash flow (DCF) valuation techniques the value of the stock is estimated based upon present value of some measure of cash flow. Free cash flow to the firm (FCFF) is generally described as cash flows after direct costs and before any payments to capital suppliers.
Paying user area
Try for free
Boston Scientific Corp. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Boston Scientific Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Intrinsic Stock Value (Valuation Summary)
Boston Scientific Corp., free cash flow to the firm (FCFF) forecast
US$ in millions, except per share data
| Year | Value | FCFFt or Terminal value (TVt) | Calculation | Present value at |
|---|---|---|---|---|
| 01 | FCFF0 | |||
| 1 | FCFF1 | = × (1 + ) | ||
| 2 | FCFF2 | = × (1 + ) | ||
| 3 | FCFF3 | = × (1 + ) | ||
| 4 | FCFF4 | = × (1 + ) | ||
| 5 | FCFF5 | = × (1 + ) | ||
| 5 | Terminal value (TV5) | = × (1 + ) ÷ ( – ) | ||
| Intrinsic value of Boston Scientific Corp. capital | ||||
| Less: 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (fair value) | ||||
| Less: Outstanding debt obligations (fair value) | ||||
| Intrinsic value of Boston Scientific Corp. common stock | ||||
| Intrinsic value of Boston Scientific Corp. common stock (per share) | ||||
| Current share price | ||||
Based on: 10-K (reporting date: 2022-12-31).
Disclaimer!
Valuation is based on standard assumptions. There may exist specific factors relevant to stock value and omitted here. In such a case, the real stock value may differ significantly form the estimated. If you want to use the estimated intrinsic stock value in investment decision making process, do so at your own risk.
Weighted Average Cost of Capital (WACC)
Boston Scientific Corp., cost of capital
| Value1 | Weight | Required rate of return2 | Calculation | |
|---|---|---|---|---|
| Equity (fair value) | ||||
| 5.50% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (fair value) | ||||
| Outstanding debt obligations (fair value) | = × (1 – ) |
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in millions
Equity (fair value) = No. shares of common stock outstanding × Current share price
= ×
=
Outstanding debt obligations (fair value). See details »
2 Required rate of return on equity is estimated by using CAPM. See details »
Required rate of return on debt. See details »
Required rate of return on debt is after tax.
Estimated (average) effective income tax rate
= ( + + + + ) ÷ 5
=
WACC =
FCFF Growth Rate (g)
FCFF growth rate (g) implied by PRAT model
Boston Scientific Corp., PRAT model
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
2022 Calculations
2 Interest expense, after tax = Interest expense × (1 – EITR)
= × (1 – )
=
3 EBIT(1 – EITR)
= Net income (loss) + Interest expense, after tax
= +
=
4 RR = [EBIT(1 – EITR) – Interest expense (after tax) and dividends] ÷ EBIT(1 – EITR)
= [ – ] ÷
=
5 ROIC = 100 × EBIT(1 – EITR) ÷ Total capital
= 100 × ÷
=
6 g = RR × ROIC
= ×
=
FCFF growth rate (g) implied by single-stage model
g = 100 × (Total capital, fair value0 × WACC – FCFF0) ÷ (Total capital, fair value0 + FCFF0)
= 100 × ( × – ) ÷ ( + )
=
where:
Total capital, fair value0 = current fair value of Boston Scientific Corp. debt and equity (US$ in millions)
FCFF0 = the last year Boston Scientific Corp. free cash flow to the firm (US$ in millions)
WACC = weighted average cost of Boston Scientific Corp. capital
FCFF growth rate (g) forecast
Boston Scientific Corp., H-model
| Year | Value | gt |
|---|---|---|
| 1 | g1 | |
| 2 | g2 | |
| 3 | g3 | |
| 4 | g4 | |
| 5 and thereafter | g5 |
where:
g1 is implied by PRAT model
g5 is implied by single-stage model
g2, g3 and g4 are calculated using linear interpoltion between g1 and g5
Calculations
g2 = g1 + (g5 – g1) × (2 – 1) ÷ (5 – 1)
= + ( – ) × (2 – 1) ÷ (5 – 1)
=
g3 = g1 + (g5 – g1) × (3 – 1) ÷ (5 – 1)
= + ( – ) × (3 – 1) ÷ (5 – 1)
=
g4 = g1 + (g5 – g1) × (4 – 1) ÷ (5 – 1)
= + ( – ) × (4 – 1) ÷ (5 – 1)
=